Literature DB >> 6305982

Isolation of a cDNA clone for human antithrombin III.

E V Prochownik, A F Markham, S H Orkin.   

Abstract

Antithrombin III (ATIII) is an important plasma protease inhibitor with a central role in the coagulation system. On the basis of its protein sequence, ATIII is one member of a "super family" of protease inhibitors that includes alpha 1-antitrypsin and chicken ovalbumin. An increased risk of thromboembolism is associated with inherited ATIII deficiency. To study the structure and expression of the human ATIII gene, we have isolated complementary (cDNA) clones for ATIII from human liver mRNA. ATIII cDNA clones were identified by hybridization to a mixture of synthetic oligodeoxynucleotides encoding amino acids 251-256 of the ATIII protein sequence. The largest cDNA clone (1.4 kilobases) included the coding region of ATIII mRNA from codon 10 through a 3'-untranslated region. Comparison of ATIII cDNA clones from two different sources revealed a sequence polymorphism at an internal PstI restriction site. Analysis of both total genomic DNAs and an ATIII gene cloned in a bacteriophage Charon 4A showed that the ATIII gene is present once per haploid genome and is distributed over 10-16 kilobases of DNA. Computer-assisted comparison of the cDNA sequence with those for baboon alpha 1-antitrypsin and chicken ovalbumin revealed homologies consistent with their inclusion in the protease inhibitor superfamily.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6305982

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  30 in total

1.  Two different genes encode delta-aminolevulinate synthase in humans: nucleotide sequences of cDNAs for the housekeeping and erythroid genes.

Authors:  D F Bishop
Journal:  Nucleic Acids Res       Date:  1990-12-11       Impact factor: 16.971

2.  Ligand-dependent enhancement of human antithrombin gene expression by retinoid X receptor alpha and thyroid hormone receptor beta.

Authors:  R W Niessen; F Rezaee; P H Reitsma; M Peters; J J de Vijlder; A Sturk
Journal:  Biochem J       Date:  1996-08-15       Impact factor: 3.857

3.  Evidence linking familial thrombosis with a defective antithrombin III gene in two British kindreds.

Authors:  S H Sacks; J M Old; S T Reeders; D J Weatherall; A S Douglas; J H Winter; C R Rizza
Journal:  J Med Genet       Date:  1988-01       Impact factor: 6.318

4.  Inhibition of chymotrypsin by heparin cofactor II.

Authors:  F C Church; C M Noyes; M J Griffith
Journal:  Proc Natl Acad Sci U S A       Date:  1985-10       Impact factor: 11.205

5.  Antithrombin III tours gene: identification of a point mutation leading to an arginine----cysteine replacement in a silent deficiency.

Authors:  N Duchange; J F Chassé; G N Cohen; M M Zakin
Journal:  Nucleic Acids Res       Date:  1986-03-11       Impact factor: 16.971

6.  Arginine residues are critical for the heparin-cofactor activity of antithrombin III.

Authors:  A M Jorgensen; C L Borders; W W Fish
Journal:  Biochem J       Date:  1985-10-01       Impact factor: 3.857

7.  Cloning and characterization of a 3-methyladenine DNA glycosylase cDNA from human cells whose gene maps to chromosome 16.

Authors:  L Samson; B Derfler; M Boosalis; K Call
Journal:  Proc Natl Acad Sci U S A       Date:  1991-10-15       Impact factor: 11.205

8.  Expression of functionally active human antithrombin III.

Authors:  A W Stephens; A Siddiqui; C H Hirs
Journal:  Proc Natl Acad Sci U S A       Date:  1987-06       Impact factor: 11.205

9.  Serine protease inhibitor antithrombin III and its messenger RNA in the pathogenesis of Alzheimer's disease.

Authors:  R N Kalaria; T Golde; S N Kroon; G Perry
Journal:  Am J Pathol       Date:  1993-09       Impact factor: 4.307

10.  Human alpha 2-HS-glycoprotein: the A and B chains with a connecting sequence are encoded by a single mRNA transcript.

Authors:  C C Lee; B H Bowman; F M Yang
Journal:  Proc Natl Acad Sci U S A       Date:  1987-07       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.